MétaCan
Menu
Back to cohort

Rate of Brain Volume Loss with Long-Term Delayed-Release Dimethyl Fumarate Treatment in Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Results from ENDORSE (P3.061)

2016· article· en· W2566136618 on OpenAlexaff
Ludwig Kappos, Tarek Yousry, Robert J. Fox, Ralf Gold, Douglas L. Arnold, James Potts, Jing L. Marantz

Bibliographic record

VenueNeurology · 2016
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsMontreal Neurological Institute and Hospital
Fundersnot available
KeywordsDimethyl fumarateRelapsing remittingMultiple sclerosisMedicineChemistryImmunology

Abstract

fetched live from OpenAlex

Objective: Evaluate the long-term rate of brain volume loss (BVL) in patients receiving continuous delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) treatment versus those switching from placebo (PBO). Background: DMF demonstrated robust efficacy and a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis in the DEFINE, CONFIRM, and ENDORSE studies. Methods: In the ENDORSE extension study, patients randomized to DMF 240 mg twice (BID) or thrice (TID) daily in DEFINE/CONFIRM continued the same dosage. PBO or glatiramer acetate (CONFIRM only) patients were re-randomized 1:1 to DMF BID or TID. Percentage brain volume change (PBVC) was calculated using the SIENA method for each MRI visit relative to baseline. BID data (approved dosage) are reported for patients continuously treated with DMF. BID and TID data were pooled for patients switching from PBO to increase sample size; Years 3-6 (ENDORSE) represent 4 years of DMF after switching. Analyses included only patients with yearly PBVC data from ENDORSE. Results: Among the DEFINE/CONFIRM MRI cohort patients who participated in ENDORSE (n=211 [BID/BID] and 206 [PBO/DMF]), 87 BID/BID and 70 PBO/DMF patients had yearly PBVC data. Using rank analysis, adjusted PBVC at Year 2 relative to DEFINE/CONFIRM baseline was significantly lower with DMF BID (median -0.5) versus PBO (median -0.79; P=0.0110). After 4 years of DMF treatment, PBVC was not significantly different for PBO/DMF versus BID/BID, relative to ENDORSE baseline. In BID/BID patients, a low annualized PBVC was observed over 6 years (mean [95[percnt] confidence interval]: -0.34/year [-0.39, -0.29]). Conclusions: In DEFINE/CONFIRM, patients treated with DMF BID had significantly reduced BVL over 2 years versus PBO. Over 6 years, annual rates of BVL in patients treated continuously with DMF were low and approached rates reported for healthy volunteers, consistent with a sustained beneficial effect of DMF on brain atrophy. Study supported by: Biogen.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.017

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.001
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.027
GPT teacher head0.253
Teacher spread0.226 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueNeurologySame topicMultiple Sclerosis Research StudiesFrench-language works237,207